Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abeona Therapeutics (ABEO) Total Liabilities (2016 - 2025)

Historic Total Liabilities for Abeona Therapeutics (ABEO) over the last 15 years, with Q3 2025 value amounting to $59.9 million.

  • Abeona Therapeutics' Total Liabilities fell 1999.09% to $59.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $59.9 million, marking a year-over-year decrease of 1999.09%. This contributed to the annual value of $64.9 million for FY2024, which is 3197.49% up from last year.
  • As of Q3 2025, Abeona Therapeutics' Total Liabilities stood at $59.9 million, which was down 1999.09% from $82.7 million recorded in Q2 2025.
  • In the past 5 years, Abeona Therapeutics' Total Liabilities ranged from a high of $83.7 million in Q1 2024 and a low of $23.3 million during Q3 2022
  • For the 5-year period, Abeona Therapeutics' Total Liabilities averaged around $49.3 million, with its median value being $46.6 million (2021).
  • As far as peak fluctuations go, Abeona Therapeutics' Total Liabilities tumbled by 4955.78% in 2022, and later soared by 14189.86% in 2024.
  • Abeona Therapeutics' Total Liabilities (Quarter) stood at $37.2 million in 2021, then increased by 0.63% to $37.5 million in 2022, then soared by 31.3% to $49.2 million in 2023, then soared by 31.97% to $64.9 million in 2024, then dropped by 7.76% to $59.9 million in 2025.
  • Its Total Liabilities stands at $59.9 million for Q3 2025, versus $82.7 million for Q2 2025 and $58.0 million for Q1 2025.